Alignment Healthcare (NASDAQ:ALHC) COO Sebastian Burzacchi Sells 15,361 Shares

Alignment Healthcare, Inc. (NASDAQ:ALHC) COO Sebastian Burzacchi sold 15,361 shares of Alignment Healthcare stock in a transaction that occurred on Wednesday, March 18th. The shares were sold at an average price of $17.84, for a total transaction of $274,040.24. Following the completion of the sale, the chief operating officer owned 258,630 shares of the company’s stock, valued at $4,613,959.20. This trade represents a 5.61% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Alignment Healthcare Stock Down 0.2%

Shares of NASDAQ ALHC traded down $0.03 during mid-day trading on Thursday, reaching $18.16. 3,987,587 shares of the company traded hands, compared to its average volume of 3,191,394. The company has a debt-to-equity ratio of 1.80, a quick ratio of 1.71 and a current ratio of 1.71. The company’s fifty day moving average is $20.57 and its two-hundred day moving average is $18.78. Alignment Healthcare, Inc. has a fifty-two week low of $11.63 and a fifty-two week high of $23.87.

Alignment Healthcare (NASDAQ:ALHC) last posted its quarterly earnings data on Thursday, February 26th. The company reported ($0.05) earnings per share for the quarter, topping the consensus estimate of ($0.15) by $0.10. The business had revenue of $1.01 billion during the quarter, compared to analysts’ expectations of $1 billion. Alignment Healthcare had a negative return on equity of 0.49% and a negative net margin of 0.02%.The firm’s revenue was up 44.4% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($0.16) EPS. Sell-side analysts forecast that Alignment Healthcare, Inc. will post -0.69 EPS for the current fiscal year.

Key Stories Impacting Alignment Healthcare

Here are the key news stories impacting Alignment Healthcare this week:

• Positive Sentiment: Recent analyst upgrades/price-target raises provide near-term support (UBS raised target to $21, Piper Sandler to $30, JPMorgan to $26), and the consensus target remains above the current price—helping underpin valuation.
• Positive Sentiment: Solid quarterly results: February quarter beat EPS and revenue estimates (revenue +44% YoY; EPS beat by $0.10), showing growth momentum in Medicare Advantage enrollment and monetization that supports longer-term upside.
• Neutral Sentiment: Zacks ran a comparison piece weighing ALHC vs. BrightSpring (BTSG) for value investors — useful context but not a company-specific catalyst. BTSG or ALHC: Which Is the Better Value Stock Right Now?
• Neutral Sentiment: Reported short-interest data is effectively zero/NaN in the recent reports (likely a reporting quirk); it doesn’t indicate a build of short pressure currently.
• Negative Sentiment: Cluster of insider sales from senior executives — President Dawn Maroney sold 30,000 shares (~$524k at $17.48) and other officers (Andreas P. Wagner, Robert L. Scavo) sold sizable blocks (~11k–12k shares each). Heavy insider selling can signal liquidity needs or personal diversification and often weighs on sentiment. Maroney sale filing: Maroney Form 4
• Negative Sentiment: Additional insider filings: Andreas P. Wagner sales (Form 4) and Robert L. Scavo sale (Form 4) were also disclosed, adding to the headline of insider liquidation. Wagner filing: Wagner Form 4 · Scavo filing: Scavo Form 4
• Negative Sentiment: Independent sell-side views: Weiss Ratings reiterated a “sell (D-)” and Wall Street Zen trimmed its rating to a hold — these dissenting views add downside risk if they influence broader investor sentiment. Weiss Ratings · Wall Street Zen reference included in company coverage.

Wall Street Analysts Forecast Growth

Several equities research analysts have weighed in on ALHC shares. Piper Sandler raised their price objective on shares of Alignment Healthcare from $20.00 to $30.00 and gave the company an “overweight” rating in a research report on Tuesday, January 6th. UBS Group boosted their target price on Alignment Healthcare from $18.00 to $21.00 and gave the company a “neutral” rating in a research note on Wednesday, January 14th. JPMorgan Chase & Co. raised their price objective on shares of Alignment Healthcare from $23.00 to $26.00 and gave the stock an “overweight” rating in a report on Thursday, February 5th. TD Cowen boosted their target price on Alignment Healthcare from $18.50 to $25.00 and gave the company a “buy” rating in a research note on Friday, January 16th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Alignment Healthcare in a research note on Wednesday, January 21st. One analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Alignment Healthcare currently has an average rating of “Moderate Buy” and an average target price of $24.56.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in ALHC. T. Rowe Price Investment Management Inc. raised its stake in Alignment Healthcare by 0.6% in the fourth quarter. T. Rowe Price Investment Management Inc. now owns 12,643,784 shares of the company’s stock valued at $249,715,000 after purchasing an additional 79,268 shares in the last quarter. Invesco Ltd. increased its holdings in Alignment Healthcare by 38.9% in the 4th quarter. Invesco Ltd. now owns 6,202,592 shares of the company’s stock valued at $122,501,000 after buying an additional 1,735,962 shares during the period. Mercer Global Advisors Inc. ADV raised its position in shares of Alignment Healthcare by 6.9% in the 4th quarter. Mercer Global Advisors Inc. ADV now owns 15,452 shares of the company’s stock valued at $305,000 after buying an additional 996 shares in the last quarter. Mackenzie Financial Corp raised its position in shares of Alignment Healthcare by 25.6% in the 4th quarter. Mackenzie Financial Corp now owns 46,917 shares of the company’s stock valued at $901,000 after buying an additional 9,552 shares in the last quarter. Finally, nVerses Capital LLC bought a new stake in shares of Alignment Healthcare during the 4th quarter worth approximately $396,000. 86.19% of the stock is owned by institutional investors.

About Alignment Healthcare

Alignment Healthcare, Inc (NASDAQ: ALHC) is a health care company specializing in value-based care for Medicare Advantage beneficiaries. The company leverages an integrated care model that combines in-home clinical services, telehealth capabilities and digital health tools to manage chronic conditions, improve outcomes and enhance patient experience.

At the core of Alignment Healthcare’s approach is a proprietary technology platform that aggregates real-time clinical and claims data to support preventive care, risk stratification and personalized care plans.